

### **Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (previously presented) A pharmaceutical composition comprising a crystalline telmisartan sodium salt and hydrochlorothiazide.
2. (original) The pharmaceutical composition according to claim 1, further comprising one or more excipients selected from mannitol, sorbitol, xylitol, saccharose, calcium carbonate, calcium phosphate, lactose, croscarmellose sodium salt, crospovidone, sodium starch glycolate, hydroxypropylcellulose, maize starch, polyvinylpyrrolidone, copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose or starch, magnesium stearate, sodium stearyl fumarate, talc, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, polyvinyl acetate, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetyl stearyl alcohol, carboxymethylcellulose, and fatty substances, or suitable mixtures thereof.
3. (cancelled)
4. (previously presented) The pharmaceutical composition according to claim 1, wherein the amount of the hydrochlorothiazide is 10 to 15 mg or 20 to 30 mg.
5. (original) The pharmaceutical composition according to claim 4, wherein the amount of the hydrochlorothiazide is 12 to 13 mg or 24 to 26 mg.
6. to 8. (cancelled)
9. (previously presented) A pharmaceutical composition comprising:
  - (a) a crystalline telmisartan sodium salt;
  - (b) hydrochlorothiazide; and
  - (c) one or more excipients selected from sorbitol, xylitol, saccharose, croscarmellose sodium salt, crospovidone, sodium starch glycolate, hydroxypropylcellulose,

polyvinylpyrrolidone, copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, sodium stearyl fumarate, hydroxypropylmethylcellulose, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetyl stearyl alcohol, carboxymethylcellulose, and fatty substances, or suitable mixtures thereof.

10. and 11. (cancelled)

12. (previously presented) The pharmaceutical composition according to claim 9, wherein the amount of the hydrochlorothiazide is 10 mg to 15 mg or 20 mg to 30 mg.

13. (original) The pharmaceutical composition according to claim 12, wherein the amount of the hydrochlorothiazide is 12 mg to 13 mg or 24 mg to 26 mg.

14. (previously presented) The pharmaceutical composition according to one of claims 1, 2, 4, 5, 9, 12, and 13, wherein the amount of the crystalline telmisartan sodium salt is 60 mg to 90 mg.

15. (previously presented) The pharmaceutical composition according to claim 14, wherein the amount of the crystalline telmisartan sodium salt is 80 mg to 85 mg.

16. (previously presented) The pharmaceutical composition according to one of claims 1, 2, 4, 5, 9, 12, and 13, wherein the amount of the crystalline telmisartan sodium salt is 30 mg to 60 mg.

17. (previously presented) The pharmaceutical composition according to claim 16, wherein the amount of the crystalline telmisartan sodium salt is 40 mg to 45 mg.

18. (previously presented) A pharmaceutical composition comprising a crystalline telmisartan sodium salt, hydrochlorothiazide, sorbitol, and magnesium stearate, compressed directly into tablets.

19. (previously presented) A pharmaceutical composition comprising:
- (a) compressed dry granules comprising a crystalline telmisartan sodium salt, mannitol, magnesium stearate, and hydroxypropylcellulose; and
  - (b) a mixture of hydrochlorothiazide, mannitol, microcrystalline cellulose, and sodium glycol starch.
20. (new) A pharmaceutical composition comprising:
- (a) a crystalline telmisartan sodium salt; and
  - (b) one or more excipients selected from sorbitol, xylitol, saccharose, croscarmellose sodium salt, crospovidone, sodium starch glycolate, hydroxypropylcellulose, polyvinylpyrrolidone, copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, sodium stearyl fumarate, hydroxypropylmethylcellulose, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetyl stearyl alcohol, carboxymethylcellulose, and fatty substances, or suitable mixtures thereof.